Overview
I am a cardiologist with a clinical and research interest in heart failure. I take care of patients with various types of heart failure, including patients who are best treated with medications and patients who receive advanced therapies like heart transplantation and mechanical assist devices. I became a heart failure cardiologist to help patients manage their heart conditions and best achieve their goals for their health. I am strongly committed to helping patients thoroughly understand their medical conditions and helping them make informed medical decisions aligned with their preferences.
My research interests are focused on strategies and therapies to improve outcomes and quality of life for patients with heart failure. This involves research through clinical trials and through examining data from real-world clinical practice. Below, you will find my specific research interests:
- Use and dosing of evidence-based heart failure medications
- Management of worsening heart failure outside the hospital
- Novel pharmacological and non-pharmacological approaches to heart failure
- Improving outcomes following a hospitalization for heart failure
- Surrogate and nonfatal endpoints in heart failure clinical trials
- Clinical trial design and operations
- Improving site-based heart failure research
Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Cardiology,
Medicine
Member in the Duke Clinical Research Institute
·
2020 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Publications
Efficacy of GLP-1 receptor agonists among older adults: a meta-analysis of cardio-kidney outcome trials.
Journal Article Archives of gerontology and geriatrics · November 2025 BackgroundOlder adults face high cardiovascular (CV) and kidney risk but may be underrepresented in randomized controlled trials (RCTs). While GLP-1RAs have been shown to provide CV and kidney benefits, estimates for efficacy and safety endpoints ... Full text CiteCardiovascular Multimorbidity in Older Adults in the United States by Race and Sex.
Journal Article JACC Adv · October 21, 2025 BACKGROUND: It is essential to understand the prevalence of cardiovascular multimorbidity and to recognize disparities by race and sex to promote health equity. OBJECTIVES: The objectives of the study are to investigate disparities in the development and p ... Full text Link to item CiteEfficacy of clopidogrel monotherapy versus aspirin monotherapy after percutaneous coronary intervention.
Journal Article J Thromb Thrombolysis · October 10, 2025 Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) is standard to reduce thrombotic complications. However, the optimal monotherapy after DAPT remains debated. Clopidogrel may offer better protection than aspirin. We condu ... Full text Link to item CiteRecent Grants
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy/Safety of Maridebart Cafraglutide on Mortality, Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction Obesity
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2025 - 2032Post-Hoc Analysis of the TRANSFORM Trial
ResearchPrincipal Investigator · Awarded by University of Texas - Southwestern · 2025 - 2026Assessing Patient Experiences with 'Food is Medicine' to Improve Congestive Heart Failure Outcomes: A Qualitative Study
ResearchCo Investigator · Awarded by American Heart Association · 2025 - 2026View All Grants
Education, Training & Certifications
Northwestern University, Feinberg School of Medicine ·
2012
M.D.